Recordati Industria Chimica e Farmaceutica S.p.A. is a global pharmaceutical group engaged in the research, development, manufacturing, and marketing of a wide range of therapeutic products. The company's business model is structured around two primary operating segments: Specialty and Primary Care (SPC) and Rare Diseases. The SPC segment, which generates the majority of the company's revenue, offers treatments across various therapeutic areas, including cardiovascular, urology, and gastroenterology, alongside over-the-counter (OTC) products. The Rare Diseases segment, operating under the Recordati Rare Diseases brand, focuses on developing and commercializing orphan drugs for metabolic, endocrine, and oncological conditions. Recordati maintains a strong geographic footprint with direct operations across Europe, the United States, Japan, and Australia, and distributes its products in over 150 countries worldwide. The company's growth strategy combines organic expansion of its existing portfolio with targeted mergers and acquisitions, as well as strategic licensing agreements to enhance its product pipeline. Recordati also manufactures active pharmaceutical ingredients (APIs) to support its internal production and for third-party sales.
